Drugs targeting inhibition of kinases for the treatment of inflammation and autoimmune disorders have become a major focus in the pharmaceutical and biotech industry. Multiple kinases from different pathways have been the targets of interest in this endeavor. This review describes some of the recent developments in the search for inhibitors of IKK2, Syk, Lck, and JAK3 kinases. It is anticipated that some of these compounds or newer inhibitors of these kinases will be approved for the treatment of rheumatoid arthritis, psoriasis, organ transplantation, and other autoimmune diseases. © Springer Science+Business Media B.V. 2008.
CITATION STYLE
Bhagwat, S. S. (2009). Kinase inhibitors for the treatment of inflammatory and autoimmune disorders. Purinergic Signalling. https://doi.org/10.1007/s11302-008-9117-z
Mendeley helps you to discover research relevant for your work.